Innovative Houston program that combines engineering, medicine to graduate inaugural class

first in class

The EnMed program is housed out of the Texas A&M University System's new Discovery Tower in the Texas Medical Center. Image via Facebook/TAMU EnMEd

Priya Arunachalam knew that she had a calling to heal, but she also has a mind for solving problems. After earning a B.S. in biomedical engineering and an MBA in healthcare management and entrepreneurship from Johns Hopkins University, the Austin native applied to medical schools knowing that her trajectory would be working as “a doctor-plus,” as she puts it.

Fortunately, a new program that combined the powers of Houston Methodist and Texas A&M University was recruiting its first graduating class. The School of Engineering Medicine allows students to simultaneously earn both a medical doctorate and a master of engineering degree in four years. It was the perfect fit.

On May 19, she will be among the 22 first students to earn those degrees. Five of them are staying on at Houston Methodist and Arunachalam is one of them.

“I am doing a general surgery residency at Houston Methodist. I am leaning towards transplant,” Arunachalam tells InnovationMap.

It’s no easy task to become a member of the EnMed program, as it’s informally known. Classes are capped at just 50 students a year, says Dr. Timothy Boone, director of education at Houston Methodist Academic Institute. He says that in the four years since EnMed launched, the size and diversity of the applicant pool has continued to grow, but it’s a very specific type of student they’re looking for.

Students must have an undergraduate degree in engineering, for one. That, Boone says, attracts problem solvers who also want to practice medicine.

“If you just think of it as a job, you’re in it for the wrong reasons,” he says.

Throughout their four years of education, students put their problem solving to the test. As they learn about medicine, the students see issues at a patient level and come up with engineering solutions.

One of Arunachalam’s creations in her time in EnMed was a redesigned hospital gown that allows for exams despite being less exposed in the back. She’s currently trying to pilot them at Houston Methodist Hospital.

Boone also mentions an ophthalmology student who has gained a preliminary patent on a design for a chair that accommodates more body types than those currently being used by most doctors. Another group of students created Go Baby Go, a toy car specifically designed for children with significant mobility impairment.

EnMed isn’t Houston Methodist’s only innovative collaboration. The University of St. Thomas Cameron School of Business joins forces with Houston Methodist to offer a master in clinical translation management program to teach students how to turn their ideas into thriving companies.

With Arunachalam’s business background, one might have expected her to follow such a path. But she says she prefers to create solutions and “find the right teams to take those ideas forward.”

Instead, her future is in surgery, which she says, is its own kind of engineering.

“I think they’re very similar," she says. "In engineering, we take apart a problem and put it back together a little better. In surgery you have a system that is malfunctioning and we have to find novel ways to fix it.”

And her and her classmates’ novel discoveries will soon be helping countless patients.

The EnMed program is graduating its first class this week. Photo via HoustonMethodist.org

Houston Methodist's Roberta Schwartz and Texas A&M University's Dr. Roderic Pettigrew shared their thought leadership at a recent panel for Houston Tech Rodeo. Photos courtesy

2 Houston experts explain what's next in health care innovation — from tech to workforce development

Houston innovators podcast episode 124

The medical field is full of problems to solve — how to improve patient care, new diseases to treat, extending but also improving quality of life, and so much more. It's an industry that needs innovation — and in many cases, that means introducing new technologies and ideas.

At last week's Houston Tech Rodeo health tech saloon, two experts weighed in on the discussion. Roberta Schwartz, chief innovation officer of Houston Methodist, and Dr. Roderic Pettigrew, dean of the Intercollegiate School of Engineering Medicine at Texas A&M University, discussed how they view the health care industry's future — and what they are doing to make sure future health care providers and innovators are ready.

“You want the next generation to get equally as excited about what’s happening in that world (of health tech) and realize how much opportunity there is to disrupt the field of health care,” Schwartz says on the panel. “It’s so natural to us at Houston Methodist to say, ‘please come along and see the opportunities there are and seize them.’”

The panelists noted on where the conversation was taking place — TAMU's new EnMed building, which was constructed and dedicated to engineering medical students. Dr. Pettigrew says the new field is meant to train problem solvers.

“When you consider scientific progress throughout history and in the future, you realize that technological innovation is the engine of scientific progress,” he says. “When you think about what profession in our society solves problems for the benefit of society, it’s engineering."

The full panel recording is available on this week's Houston Innovators Podcast. Listen to it below — or wherever you stream your podcasts — and subscribe for weekly episodes.



Photo courtesy of Houston Methodist

Health care innovators joined Houston Methodist and Texas A&M University's ENMED program to discuss women in health care innovation and venture capital investment. Photo courtesy of Houston Methodist

Overheard: Houston experts discuss women in med tech, insight from investors, and more

Eavesdropping in Houston

Houston's health innovation community is making strides every day toward greater quality of care and technology adoption — but what challenges is the industry facing these days?

Through a partnership between Houston Methodist and Texas A&M University's ENMED program at Houston Tech Rodeo, health innovators weighed in on topics surrounding the industry, including biases and investment opportunities.

Missed the conversation? Here are seven key moments from the panels that took place at A&M's new ENMED building in the Texas Medical Center on Thursday, March 3.

“When I look at learning and understanding the priorities — how to take care of patients and also enable those who are doing that work, that’s part of understanding the culture and learning because in the 40 years that I’ve been in the industry, it’s never been the same. There are always things that continue to present challenges from unexpected places.”

​— Ayse McCracken, founder of Ignite Healthcare Network, says on the "Four Fierce Females" panel, referencing the rate of tech disruption and how new technologies, medicine, etc. can change the health care industry and practitioners need to find ways to keep up and stay ahead of the curve.

“Whenever you experience biases, what can you do? You can lean into the fact that we are in a position to help educate and make a change. And that’s going to look different for every one of us, but lean into that instead of feeling down by it.”

— Samantha Lewis, principal at Mercury Fund, says on the "Four Fierce Females" panel, explaining that women across industries should lean into being a change agent when met with bias in the workplace.

“The reason I feel so passionate is (I’m always thinking,) ‘What more can we be doing for our community? What’s working well and what’s not working well,' so I can take that back and make positive changes in our organization.”

— Michelle Stansbury, vice president of innovation and IT applications at Houston Methodist, says on the "Four Fierce Females" panel, explaining that when she's on the other side of the equation as a patient, she really considers her experience and how it could be better.

“Every time you raise money you’re telling a story. You have to figure out what adds value to that story. … I think health care is tricky too because people getting into it aren’t necessarily aware of how complex it is.”

— Dan Watkins, venture partner and co-founder at Mercury Fund, says on the "Where’s My Money At?" investor panel, adding how important it is to investors that founders have specific information — market potential, road map, etc. — when pitching to VCs.

“As a health care startup founder and CEO, you have to wear so many different hats — especially if you’re talking about diagnostics and medical devices. It starts in the science, moves to engineering, and then winds up being commercial. To expect someone to be an expert at all those fields is very difficult.”

— Tim Marx, venture partner at Baird Capital, says on the "Where’s My Money At?" investor panel, adding that, “That’s why we look for the CEOs who really understand where they are, where they’re going, and what they need.”

“One of the things we really appreciate when we engage with founders, it’s not about ‘here’s why my company is great.’ It’s more about understanding the questions your business needs to answer. … If you think about that, that’s what we want to fund. We want to invest in the vision, opportunity, and the people, but we want to fund the — the roadmap — that usually comes with being thoughtful about the questions you’re trying to answer.”

— John Reale, venture lead at TMC Venture Fund, says on the "Where’s My Money At?" investor panel, adding "That's where we get energized."

“The idea to attract talent that’s already built great companies across the US and the world to come here, hire here, and grow here — that’s starting to actually pay off. One of the things that’s big about Houston is it’s really gritty — it’s very ‘show me the data and prove it to me first.’ … We’re having those proven points.”

— Emily Reiser, associate director of innovation at the Texas Medical Center , says on the "Where’s My Money At?" investor panel about the work TMC is doing with its accelerator program.

It's pay day for several Houston-area research teams thanks to two grant programs. Photo via Getty Images

Several Houston-area life science research teams receive thousands in grants

research roundup

Several health innovation research teams across Houston are celebrating fresh funds to go toward the development of breakthrough technologies and research projects.

In InnovationMap's latest roundup of research news, check out who received this crucial funding and how their research and work can change the standard of care across the life science industry.

Reliant doles out $100,000 to two Houston Methodist critical care physician-scientists

Reliant announced that the recipients of the Reliant Innovation Fund will be two individuals within Houston Methodist Center for Critical Care in collaboration with Texas A&M's Engineering Medicine (EnMed) program.

"Meaningful innovation is core to us at Reliant and the work these institutions, physicians and students are doing is truly amazing," says Elizabeth Killinger, president of Reliant, in a news release. "We appreciate how Houston Methodist is making a lasting difference in our community by continuing to revolutionize medicine and we are honored to support them through the EnMed program."

Dr. Hina Faisal and Dr. Asma Zainab — along with the EnMed students who will support their work — will use the funds to advance their work. An anesthesiologist and critical care physician, Faisal will lead a project on 3-D-simulated virtual reality technology to prevent delirium in critically ill patients. Zainab, who specializes in cardiovascular ICU and focuses on respiratory failure and ventilator use, will lead a project to help personalize care in lung failure, creating models specific to each patient to avoid unnecessary pressure and injury caused by ventilators, per the release.

"Innovation is at the heart of what we do," says Dr. Faisal Masud, director of the Center of Critical Care at Houston Methodist, in the release. "Thanks to Reliant's generous contribution and ongoing support, we are able to seek out new ways to provide the best quality care for our most vulnerable patients while supporting our physicians, our students and their research."

Researchers at Rice University and Texas Medical Center institutions snag grants

Six research teams have received funding from Rice University's Educational and Research Initiatives for Collaborative Health, known as ENRICH. Established in 2016, the program focuses on connecting Rice faculty with TMC institutions to encourage collaboration. Last year, more than a fifth of Rice faculty were engaged in active collaborations with TMC research partners, according to a news release.

"Partnerships with TMC are an institutional priority, and they enable our faculty to translate their research to clinical practice, directly benefiting the Houston community," says Marcia O'Malley, special advisor to the provost on ENRICH and the Thomas Michael Panos Family Professor in Mechanical Engineering, in the release. "ENRICH has been instrumental in facilitating faculty engagement with TMC partners, reducing barriers to collaboration and investing institutional resources in new partnerships."

The Provost's TMC Collaborator Fund awarded $60,000 in grants to:

  • Jason Hafner '98, professor of physics and astronomy at Rice, and Carly Filgueira '09, assistant professor of nanomedicine and cardiovascular surgery at Houston Methodist Research Institute, to explore the development of an optical sensor for clinical detection of cholesterol.
  • Lan Li, assistant professor of history at Rice; Ricardo Ernesto Nuila, associate professor of medicine, medical ethics and health policy at Baylor College of Medicine; and Fady Joudah, a poet, literary translator and physician at Baylor St. Luke's Medical Center, for a pilot study of community health care access that addresses larger questions about medical racism in Houston.
  • Oleg Igoshin, professor of bioengineering at Rice, and Anna Konovalova, assistant professor of microbiology and molecular genetics at the University of Texas Health Science Center at Houston's McGovern Medical School, to explore new targets for antibiotic treatment by probing the feedback loop between two important stress-response pathways in bacteria.
Additionally, Rice ENRICH and Baylor's Interdisciplinary Surgical Technology and Innovation Center (INSTINCT) awarded $60,000 in grants to:
  • Pulickel Ajayan, the Benjamin M. and Mary Greenwood Anderson Professor in Engineering and chair of Rice's Department of Materials Science and Nanoengineering, and Crystal Shin, assistant professor of surgery at Baylor, for development of a self-charging, wireless microsensor capable of detecting changes in flow in blood vessels that have been replaced in heart bypass surgery.
  • Meng Li, Noah Harding Assistant Professor in Statistics at Rice, and Gabriel Loor, associate professor of surgery at Baylor, to study inflammation following lung transplantation and search for the cause of inflammatory responses that differ between men and women.
  • Vaibhav Unhelkar, assistant professor of computer science at Rice, and James Suliburk, associate professor of surgery at Baylor, to explore how artificial intelligence can augment surgical training.


Reliant and Aramco Americas have provided Houston Methodist funds to move forward pertinent research and opportunities. Courtesy of Methodist Hospital/Facebook

2 corporations write checks to go toward Houston hospital's COVID-19 efforts

money moves

Two Houston companies have doled out cash to a Houston hospital's efforts in driving innovation during the pandemic as well as moving forward in a post-COVID-19 world.

Houston Methodist received $500,000 from Houston-based Aramco Americas and $130,000 from Houston-based Reliant. Aramco's gift will go toward funding ongoing research on convalescent plasma therapy as a treatment for COVID-19 and Reliant's donation will create the Reliant Innovation Fund.

"The challenges that we have and will continue to face with the COVID-19 pandemic amplifies the need for fresh ideas to combat this disease and treat those who have been affected," says Dr. Faisal Masud, medical director of the Center for Critical Care at Houston Methodist Hospital, in a news release from Reliant. "Innovating is at the core of what we do at Houston Methodist, and this generous gift from Reliant will make a difference for patients both now and for years to come."

According to the release, $100,000 will go toward supporting students in the Texas A&M University's Engineering Medicine program, which combines engineering and medical courses to allow for students to receive a master's in engineering and a medical degree in four years. Currently, A&M is renovating a building in the Texas Medical Center that will be the future home of the program.

"The EnMed program is educating a new type of physician — one with an engineering background and a forward-thinking, innovative medical mindset. Reliant's partnership and donation will allow our students to innovate for the dynamic needs on today's clinical front lines," says Dr. Timothy Boone, director of the Houston Methodist Education Institute and Associate Texas A&M Dean, in the release.

The other $30,000 of Reliant's gift will go towards expanding the hospital's patient-centric mobile app, CareSense, which Houston Methodist has used to connect with COVID-19 patients after they have left the hospital.

Aramco's donation will be used to support Houston Methodist's plasma research on COVID-19 treatment. The hospital was the first academic medical center in the United States to get FDA approval for this type of treatment on COVID-19 patients.

"Convalescent plasma therapy has been effective in other infectious diseases and our physician-scientists are working to develop it into a first-line treatment for COVID-19," says Dr. Dirk Sostman, president at the Houston Methodist Academic Institute, in a news release from Aramco.

The treatment collects blood from recovered COVID-19 patients and infuses the plasma into currently ill COVID-19 patients in hopes that the recovered patient's plasma can provide the antibodies for the ill patient to fight off the disease.

"Houston Methodist Hospital is a world-leader in healthcare as well as research and development," says Mohammad S. Alshammari, president and CEO of Aramco Americas in the release. "Our donation is an opportunity to support the innovative work occurring there in support of the Houston community and to contribute to long-term medical solutions for this global health crisis."

Texas A&M University is planning a three-building project to bring parking, housing, retail, and more to the Texas Medical Center. Photo courtesy of Texas A&M University System

Texas A&M University reveals plans for $546M medical complex in Houston

coming soon

Texas A&M University has announced a new three-building project in the Texas Medical Center that will bring a renovated space for its Engineering Medicine program, student housing, parking, retail, and more.

The $546 million complex will be funded in part by a public-private partnership, according to a news release from the university. The project includes one 18-story building to be purchased and renovated for $145 million, and an additional $401 million will go toward constructing two new buildings.

"The Board of Regents of the Texas A&M University System recognized an opportunity in Houston to help Texans and contribute more to the global medical community," says Elaine Mendoza, chairman of the Board of Regents of the Texas A&M University System, in the news release. "We are eager and fortunate to further enhance the world's greatest medical center through this endeavor."

The first of the three buildings to debut will be the EnMed renovation project at 1020 Holcombe Blvd. This project, which had previously been announced, is expected to deliver by this summer and should be monumental for the already successful program, says Bob Harvey, president and CEO of the Greater Houston Partnership, in a statement.

"Texas A&M's EnMed program fits right into what we are doing in Houston," Harvey says. "Our city has long been recognized as a destination for world-class health care and cutting-edge research, thanks to the incredible institutions in the Texas Medical Center. Houston is also becoming known as an attractive location for both mature and emerging life science and biotech companies. We are, indeed, becoming the 'third coast' for life sciences."

A&M TMCThe first of the three buildings is expected to be complete this summer. Photo courtesy of Texas A&M University System

The two new construction buildings will be paid for through public-private partnerships. The student housing building, a 19-story building planned to have 572 units with 704 beds in a 365,000 square-foot space, will be completed by June 2022, according to the release. The building will also include a 3,444-spot parking garage. Students from A&M campuses will get priority housing, but students at other institutions will also be allowed spots if available.

"We saw a need for student housing and medical offices in Houston. Plus, our EnMed students needed the facilities to create the latest medical devices," says Greg Hartman, a vice chancellor at Texas A&M University System and interim senior vice president of the Texas A&M Health Science Center, in a news release. "So, we began the process of expanding the Texas A&M footprint in Houston and I believe the work done by Aggies in Houston will be life-changing for a lot of people."

The third component of the plans includes a 587,000-square-foot, 30-floor Integrated Medical Plaza — another public-private partnership — and it has a June 2023 expected completion. Thirteen of the stories will be parking, and 72,000 square feet of space will be for retail use, while 8,700 square feet will be green space.

According to the release, the developer for the two new construction projects is Houston-based Medistar Corp., which is run by CEO Monzer Hourani. New York-basedAmerican Triple I Partners is on the financing team and was founded by Henry Cisneros, a Texas A&M alumnus.

Representatives from both the school and the city see the potential impact of the complex for medical innovations.

"Last year, Houston had its best year ever in terms of attracting venture capital to the region," Harvey says in his statement on the news. "This program and this facility will provide one more reason for major VCs to give Houston's innovative companies a look – and for talented students, researchers, and entrepreneurs to make Houston their home."

Dr. M Katherine Banks, who serves the university of vice chancellor of engineering and national laboratories at the Texas A&M System, notes in the release how the EnMed program has set up its students for breakthrough medical device innovation.

"I expect to see transformative ideas generated by Texas A&M's broadened presence in Houston," says Dr. Banks in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

View All Listings